Homology Medicines to Participate at Upcoming Conferences
Homology Medicines, Inc. (Nasdaq: FIXX) announced its participation in key conferences, highlighting its commitment to advancing genetic medicine. On October 11, CEO Albert Seymour will present at the Cell & Gene Meeting on the Mesa and participate in a panel discussion. Chairman Arthur Tzianabos will also speak on new business models for manufacturing investments. Additionally, at the American Society of Human Genetics Annual Meeting on October 26, the company will present research on gene editing and a clinical study for phenylketonuria (PKU).
- None.
- None.
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences.
- Cell & Gene Meeting on the Mesa
- Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT
- “Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic” panel featuring Dr. Seymour on
October 11 at 4:00 p.m. PT - “New Business Models for Manufacturing Investment” panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at
3:15 p.m. PT
- American Society of Human Genetics (ASHG) 2022 Annual Meeting: Poster Presentations on October 26 at 3:00 p.m. PT
- “Single-Molecule, Modified Base Sequencing to Identify Frequency and Cause of rAAV Vector Breakpoints”
- “A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of HMI-103, a One-Time Gene-Editing Vector in Adult Participants with Classical PKU Due to PAH Deficiency”
About Homology Medicines, Inc.
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU). Additional programs focus on metachromatic leukodystrophy (MLD), paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.
Company Contacts
Theresa McNeely
Chief Communications Officer
and Patient Advocate
tmcneely@homologymedicines.com
781-301-7277
Media Contact:
Cara Mayfield
Vice President, Patient Advocacy
and Corporate Communications
cmayfield@homologymedicines.com
781-691-3510
FAQ
What conferences is Homology Medicines attending in October 2022?
Who will present at the Cell & Gene Meeting on the Mesa?
What topics will be discussed at the Cell & Gene Meeting on the Mesa?
What research will be presented by Homology Medicines at the ASHG 2022 Annual Meeting?
What is Homology Medicines' focus in genetic medicine?
